Adjuvant Alectinib Impresses in Updated ALINA Results for ALK+ NSCLC - OncLive

Adjuvant Alectinib Impresses in Updated ALINA Results for ALK+ NSCLC  OncLive

Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC - CancerNetwork

Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC  CancerNetwork

ALEX Trial Final Results at ESMO 2025: Alectinib Demonstrates Durable Overall Survival and Long-T...

ALEX Trial Final Results at ESMO 2025: Alectinib Demonstrates Durable Overall Survival and Long-Term Disease Control in Advanced ALK-Positive NSCLC  Oncodaily

Implications of the ALINA Trial: Is It Time to Skip Adjuvant Chemotherapy in ALK-Positive NSCLC? ...

Implications of the ALINA Trial: Is It Time to Skip Adjuvant Chemotherapy in ALK-Positive NSCLC?  ASCO Daily News

Safety of Alectinib Versus Crizotinib in the Adjuvant Setting for Patients With ALK+ NSCLC - Canc...

Safety of Alectinib Versus Crizotinib in the Adjuvant Setting for Patients With ALK+ NSCLC  Cancer Nursing Today

Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in...

Alectinib boosts anti-tumor efficacy of disialoganglioside 2 chimeric antigen receptor T cells in ALK -mutated neuroblastoma by suppressing programmed death-ligand 1  Nature

Adjuvant ALK TKIs show robust and durable disease-free survival benefit in non-small cell lung ca...

Adjuvant ALK TKIs show robust and durable disease-free survival benefit in non-small cell lung cancer  ESMO Daily Reporter

Neoadjuvant Alectinib in a Patient With Anaplastic Lymphoma Kinase (ALK)-Mutant Stage III Lung Ad...

Neoadjuvant Alectinib in a Patient With Anaplastic Lymphoma Kinase (ALK)-Mutant Stage III Lung Adenocarcinoma: A Case Report  Cureus

Computational drug repurposing reveals Alectinib as a potential lead targeting Cathepsin S for th...

Computational drug repurposing reveals Alectinib as a potential lead targeting Cathepsin S for therapeutic developments against cancer and chronic pain  Frontiers

'Blow Your Mind' Survival Improvement in Advanced, Mutated NSCLC - MedPage Today

'Blow Your Mind' Survival Improvement in Advanced, Mutated NSCLC  MedPage Today

Complement C1q-Targeted Microglial Membrane Camouflaged Nanolipid Carriers for Synaptic Protectio...

Complement C1q-Targeted Microglial Membrane Camouflaged Nanolipid Carriers for Synaptic Protection in Alzheimer’s Disease: A Bioinspired Alectinib Delivery Strategy  ACS Publications

Phase III ALINA Trial Shows Adjuvant Alectinib Has ‘Clinically Meaningful’ Benefits for ALK+ NSCL...

Phase III ALINA Trial Shows Adjuvant Alectinib Has ‘Clinically Meaningful’ Benefits for ALK+ NSCLC  Cancer Nursing Today

Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small ce...

Alectinib in combination with bevacizumab as first-line treatment in ALK -rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial  Nature

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC - CancerNetwork

Neoadjuvant Alectinib Effective, Tolerable in Late-Stage ALK-Positive NSCLC  CancerNetwork

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung ca...

Perforation of the descending colon induced by alectinib in a patient with non-small cell lung cancer: a Case Report  Frontiers

Dr Mok on Final OS Data From the ALEX Study Evaluating First-Line Alectinib in ALK+ NSCLC - OncLive

Dr Mok on Final OS Data From the ALEX Study Evaluating First-Line Alectinib in ALK+ NSCLC  OncLive

Study Investigates Tailored Sequencing Strategies to Extend Survival in ALK-Positive Advanced NSC...

Study Investigates Tailored Sequencing Strategies to Extend Survival in ALK-Positive Advanced NSCLC  Cancer Nursing Today

Dr Lee on Disease-Free Survival Outcomes With Alectinib in ALK+ NSCLC - OncLive

Dr Lee on Disease-Free Survival Outcomes With Alectinib in ALK+ NSCLC  OncLive

Study Compares Effectiveness of First-Line TKIs in Patients With ALK+ NSCLC and Brain Metastases ...

Study Compares Effectiveness of First-Line TKIs in Patients With ALK+ NSCLC and Brain Metastases  Cancer Nursing Today

Postoperative Crizotinib Fails in Early Lung Cancer - MedPage Today

Postoperative Crizotinib Fails in Early Lung Cancer  MedPage Today

FDA Approves Alectinib for ALK-Positive Lung Cancer - National Cancer Institute (.gov)

FDA Approves Alectinib for ALK-Positive Lung Cancer  National Cancer Institute (.gov)

Oncology Letters - Spandidos Publications

Oncology Letters  Spandidos Publications

Advanced ALK-Positive NSCLC: Treatment Sequencing Insights From ASCO 2025 - Cancer Therapy Advisor

Advanced ALK-Positive NSCLC: Treatment Sequencing Insights From ASCO 2025  Cancer Therapy Advisor

Lung Adenocarcinoma Expressing an EML4-ALK Fusion Transcript With Premature Stop Codons and Respo...

Lung Adenocarcinoma Expressing an EML4-ALK Fusion Transcript With Premature Stop Codons and Response to Alectinib: A Case Report  Wiley Online Library

First Russian generic of Alecensa to be 40% cheaper than original drug - Новости GxP

First Russian generic of Alecensa to be 40% cheaper than original drug  Новости GxP

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma ...

Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib  Frontiers

ALNEO Phase II Trial Highlights Promising Role of Perioperative Alectinib in Stage III Resectable...

ALNEO Phase II Trial Highlights Promising Role of Perioperative Alectinib in Stage III Resectable ALK-Positive NSCLC  Oncodaily

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer - The New England Journal of Medicine

Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer  The New England Journal of Medicine

Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC - Oncol...

Alectinib Reduces Risk of Recurrence or Death by 76% in Early-Stage, Resected, ALK+ NSCLC  Oncology Nursing News

ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms race - S...

ALK inhibitors against resistance in non-small cell lung cancer: an 18 year medical arms race  ScienceDirect.com

Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Ty...

Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types  BioSpace

Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-posit...

Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer  Wiley Online Library

Beating the Odds: A Successful Pregnancy in a Patient With ALK-Rearranged Lung Cancer on Alectini...

Beating the Odds: A Successful Pregnancy in a Patient With ALK-Rearranged Lung Cancer on Alectinib  Wiley Online Library

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC - Targeted Oncology

Brigatinib Not Superior to Alectinib in ALK-Positive NSCLC  Targeted Oncology

From Cholesterol Management to Self-Image Concerns: What Nurses Should Know About ALK+ NSCLC - Ca...

From Cholesterol Management to Self-Image Concerns: What Nurses Should Know About ALK+ NSCLC  Cancer Nursing Today

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunit...

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity  Nature

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer - Pharmacy Times

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer  Pharmacy Times

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer - The New Engla...

Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer  The New England Journal of Medicine

CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting - ASCO Daily News

CROWN Trial 5-Year Update: Lorlatinib Is the Frontrunner in the Frontline Setting  ASCO Daily News

Adjuvant alectinib is a new treatment strategy for resected ALK-positive NSCLC - ESMO Daily Reporter

Adjuvant alectinib is a new treatment strategy for resected ALK-positive NSCLC  ESMO Daily Reporter

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC - OncLive

Adjuvant Alectinib Is Associated With a Tolerable Safety Profile in ALK+ NSCLC  OncLive

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib...

Changes in Red Cell Morphology and Haematological Laboratory Parameters Associated With Alectinib  Wiley Online Library

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC - OncLive

Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC  OncLive

FDA Approves Alectinib for Early-Stage ALK+ NSCLC - CancerNetwork

FDA Approves Alectinib for Early-Stage ALK+ NSCLC  CancerNetwork

Case Report: Metastatic colorectal cancer with ALK–CEP44 fusion and rapid resistance development ...

Case Report: Metastatic colorectal cancer with ALK–CEP44 fusion and rapid resistance development  Frontiers

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer - National Cancer Instit...

FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer  National Cancer Institute (.gov)

Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib - Cancer Therapy ...

Brigatinib, Alectinib Produce Similar PFS After NSCLC Progression on Crizotinib  Cancer Therapy Advisor

Adjuvant alectinib has been approved by the FDA for resected ALK-positive NSCLC - ESMO Daily Repo...

Adjuvant alectinib has been approved by the FDA for resected ALK-positive NSCLC  ESMO Daily Reporter

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive ...

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study  The Lancet

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer - Na...

Fibroblasts and alectinib switch the evolutionary games played by non-small cell lung cancer  Nature

Alectinib and Pembrolizumab for Non-Small Cell Lung Cancers - Medscape

Alectinib and Pembrolizumab for Non-Small Cell Lung Cancers  Medscape

Alectinib Fails to Improve OS in ALK-Positive NSCLC - OncLive

Alectinib Fails to Improve OS in ALK-Positive NSCLC  OncLive

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports - Fron...

Appendicitis while on alectinib for non-small cell lung cancer: a tale of two case reports  Frontiers

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptot...

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation  Nature

Alectinib “First of Many Approvals” In ALK+ NSCLC - CancerNetwork

Alectinib “First of Many Approvals” In ALK+ NSCLC  CancerNetwork

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC - OncLive

FDA Approves Adjuvant Alectinib for ALK+ Early-Stage NSCLC  OncLive

Alectinib Approved for ALK-Positive Adjuvant NSCLC - Medscape

Alectinib Approved for ALK-Positive Adjuvant NSCLC  Medscape

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC - OncLive

Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC  OncLive

Substantial Meals Can Elevate Lung Cancer Drug Concentration - Cure Today

Substantial Meals Can Elevate Lung Cancer Drug Concentration  Cure Today

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC - CancerNetwork

Alectinib Significantly Improves DFS Vs Chemo in Resected ALK+ NSCLC  CancerNetwork

Genprex (NASDAQ: GNPX) posts positive preclinical data on REQORSA in NSCLC - Stock Titan

Genprex (NASDAQ: GNPX) posts positive preclinical data on REQORSA in NSCLC  Stock Titan

Clinical Case: ALK-Positive Advanced NSCLC - Oncology Nursing News

Clinical Case: ALK-Positive Advanced NSCLC  Oncology Nursing News

Alecensa (alectinib): Side effects, dosage, and more - Medical News Today

Alecensa (alectinib): Side effects, dosage, and more  Medical News Today

A New Molecularly Targeted Therapy for Lung Cancer - American Association for Cancer Research (AACR)

A New Molecularly Targeted Therapy for Lung Cancer  American Association for Cancer Research (AACR)

Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC - OncLive

Dr Nieva on the Rationale for Comparing ALK Inhibitors in ALK+ NSCLC  OncLive

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC - CancerNetwork

Adjuvant Alectinib Earns European Approval in Resectable ALK+ NSCLC  CancerNetwork

FDA Approves Adjuvant Alectinib for ALK-Positive NSCLC - Oncology News Central

FDA Approves Adjuvant Alectinib for ALK-Positive NSCLC  Oncology News Central

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resist...

CCN1 is a therapeutic target upregulated in EML4-ALK mutant lung adenocarcinoma reversibly resistant to alectinib  Nature

Alectinib Improves DFS Over Chemotherapy in Early-Stage, ALK+ NSCLC - Oncology News Central

Alectinib Improves DFS Over Chemotherapy in Early-Stage, ALK+ NSCLC  Oncology News Central

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC - Oncod...

Oscar Arrieta: Alectinib Plus Bevacizumab as First-Line Treatment in ALK-Rearranged NSCLC  Oncodaily

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer - Wile...

Dramatic response to alectinib in a patient with ALK -rearranged squamous cell lung cancer  Wiley Online Library

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma - Nature

Complete response to alectinib in ALK-fusion metastatic salivary ductal carcinoma  Nature

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an...

Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial  The Lancet

ALK-Positive NSCLC: Adjuvant Alectinib vs Platinum-Based Chemotherapy - The ASCO Post

ALK-Positive NSCLC: Adjuvant Alectinib vs Platinum-Based Chemotherapy  The ASCO Post

FDA Approves Adjuvant Alectinib in ALK+ NSCLC - Targeted Oncology

FDA Approves Adjuvant Alectinib in ALK+ NSCLC  Targeted Oncology

Luis Lara-Mejía: Early Resistance in ALK+ NSCLC Targeted with Alectinib and Bevacizumab Combo - O...

Luis Lara-Mejía: Early Resistance in ALK+ NSCLC Targeted with Alectinib and Bevacizumab Combo  Oncodaily

VisualAbstract: Alectinib Improves Disease-Free Survival in ALK-Positive Non-Small-Cell Lung Canc...

VisualAbstract: Alectinib Improves Disease-Free Survival in ALK-Positive Non-Small-Cell Lung Cancer Compared to Platinum-Based Chemotherapy  2 Minute Medicine

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK -Positive...

ALINA Trial: Adjuvant Alectinib Improves Survival vs Platinum-Based Chemotherapy in ALK -Positive NSCLC  The ASCO Post

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-pos...

Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer  Nature

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on...

FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer based on ALINA trial  Oncodaily

Diet May Have Big Effect on Common Lung Cancer Treatment - Inside Precision Medicine

Diet May Have Big Effect on Common Lung Cancer Treatment  Inside Precision Medicine

Hemolytic anemia following alectinib reported to the U.S. Food and Drug Administration Adverse Ev...

Hemolytic anemia following alectinib reported to the U.S. Food and Drug Administration Adverse Event Reporting System  Wiley Online Library

Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK ...

Real-world therapeutic effectiveness of lorlatinib after alectinib in Japanese patients with ALK -positive non-small-cell lung cancer  Wiley Online Library

These 33 Life-Saving Drugs, Including Daratumumab, Alectinib, Obinutuzumab, Now GST-Free, See Lis...

These 33 Life-Saving Drugs, Including Daratumumab, Alectinib, Obinutuzumab, Now GST-Free, See List  Medical Dialogues

Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC - ESMO Daily Reporter

Alectinib shows benefit across genetic profiles in resected ALK-positive NSCLC  ESMO Daily Reporter

Incidence of Cardiac AEs With Alectinib Higher Than Expected in ALK+ NSCLC - Oncology Nurse Advisor

Incidence of Cardiac AEs With Alectinib Higher Than Expected in ALK+ NSCLC  Oncology Nurse Advisor

Cancer drug alectinib less effective when taken with low-fat yogurt - Healio

Cancer drug alectinib less effective when taken with low-fat yogurt  Healio

Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or ...

Profound and sustained response with next-generation ALK inhibitors in patients with relapsed or progressive ALK-positive anaplastic large cell lymphoma with central nervous system involvement  Haematologica

Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cance...

Alectinib Yields Better Overall Survival Than Ceritinib in ALK-Positive Non–Small Cell Lung Cancer  CancerNetwork

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage...

ALINA: Efficacy and Safety of Adjuvant Alectinib Versus Chemotherapy in Patients With Early-Stage ALK+ NSCLC  OncLive

Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination ...

Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors  Nature

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and liter...

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review  Frontiers

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-sm...

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK -rearranged non-small cell lung cancer  Wiley Online Library

For Alecensa, ‘Take With Meal’ May Have a Caveat - Managed Healthcare Executive

For Alecensa, ‘Take With Meal’ May Have a Caveat  Managed Healthcare Executive

Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers - Cancer Therapy Ad...

Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers  Cancer Therapy Advisor

Alectinib Approved for ALK-Positive NSCLC - National Cancer Institute (.gov)

Alectinib Approved for ALK-Positive NSCLC  National Cancer Institute (.gov)

Alectinib for Relapsed/Refractory ALK+ NSCLC - OncLive

Alectinib for Relapsed/Refractory ALK+ NSCLC  OncLive

Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resou...

Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings  Nature

Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcino...

Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma  Cureus

First-Line ALK-Positive NSCLC With CNS Metastases at Baseline - The ASCO Post

First-Line ALK-Positive NSCLC With CNS Metastases at Baseline  The ASCO Post